Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 6/20 | 0.77 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.77 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.77 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.77 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.77 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.77 |
| ▸ | HTR1D | P28221 | 1/20 | 0.69 |
| ▸ | HTR7 | P34969 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8020019 | 0.87 | ADRA2A (1.00) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL11203702 | 0.86 | ADRA2A (0.60) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL11187432 | 0.84 | ADRA2A (0.72) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL29412295 | 0.84 | ADRA2A (0.65) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL29411887 | 0.84 | ADRA2A (0.64) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL5612448 | 0.82 | ADRA2A (0.61) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL4760243 | 0.81 | HTR1D (1.00) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL11169014 | 0.81 | ADRA1A (0.77) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| Hydrochloric Acid SCHEMBL29384552 | 0.80 | HTR1D (0.97) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL11160689 | 0.78 | ADRA2A (0.71) | ADRA2AADRA1AADRA2BADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4180482-B1 | MOISTURE-CURABLE COMPOSITION | NITTO KASEI CO LTD (JP) | 2025-12-03 | — | — | EP | disclosed |
| US-12479869-B2 | Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product | NITTO KASEI CO., LTD. (JP) | 2025-11-25 | — | — | US | disclosed |
| EP-4174053-B1 | CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT | NITTO KASEI CO LTD (JP) | 2025-11-19 | — | — | EP | disclosed |
| EP-4569023-A1 | COMBINATION OF CATALYTIC COMPONENTS | PolyU GmbH (DE) | 2025-06-18 | — | — | EP | disclosed |
| CN-115516041-B | Curing catalyst for curing polymer, method for producing same, moisture-curable composition, and method for producing cured product | 日东化成株式会社 | 2024-06-28 | — | — | CN | disclosed |
| WO-2024033348-A1 | COMBINATION OF CATALYTIC COMPONENTS | POLYU GMBH (DE) | 2024-02-15 | — | — | WO | disclosed |
| EP-4321573-A1 | COMBINATION OF CATALYTIC COMPONENTS | PolyU GmbH (DE) | 2024-02-14 | — | — | EP | disclosed |
| US-20230234976-A1 | CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT | NITTO KASEI CO., LTD. (JP) | 2023-07-27 | — | — | US | disclosed |
| EP-4180482-A1 | MOISTURE-CURABLE COMPOSITION | Nitto Kasei Co., Ltd. (JP) | 2023-05-17 | — | — | EP | disclosed |
| EP-4174053-A1 | CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT | Nitto Kasei Co., Ltd. (JP) | 2023-05-03 | — | — | EP | disclosed |
| US-20110237723-A1 | CURABLE COMPOSITION AND CURED PRODUCT THEREOF | KANEKA CORPORATION (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-2338938-A1 | CURABLE COMPOSITION AND CURED PRODUCT THEREOF | Kaneka Corporation (JP) | 2011-06-29 | — | — | EP | disclosed |
| US-7960459-B2 | Curable composition | KANEKA CORPORATION (JP) | 2011-06-14 | — | — | US | disclosed |
| EP-2267083-A1 | CURABLE COMPOSITION AND CURED MATERIAL | Kaneka Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-1990371-B1 | CURABLE COMPOSITION | KANEKA CORP (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20090209422-A1 | Insecticidal Substituted Aminoalkyl Heterocyclic and Heteroaryl Derivatives | BAYER CROPSCIENCE AG (DE) | 2009-08-20 | — | — | US | disclosed |
| US-20090186993-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1990371-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-11-12 | — | — | EP | disclosed |
| EP-1879455-A1 | INSECTICIDAL SUBSTITUTED AMINOALKYL HETEROCYCLIC AND HETEROARYL DERIVATIVES | Bayer CropScience AG (DE) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006119411-A1 | INSECTICIDAL SUBSTITUTED AMINOALKYL HETEROCYCLIC AND HETEROARYL DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479869-B2 | Curing catalyst used for curing of polymer, method for producing same, moisture-curable composition, and method for producing cured product | KDM2B, SETDB1, ASH2L | ADRA2A 3479/4885ADRA1A 3189/4885ADRA2B 1673/4885 |
| US-20090209422-A1 | Insecticidal Substituted Aminoalkyl Heterocyclic and Heteroaryl Derivatives | DDT, AADAC, DDC | ADRA2A 570/4885ADRA1A 799/4885ADRA2B 728/4885 |
| US-20230234976-A1 | CURING CATALYST USED FOR CURING OF POLYMER, METHOD FOR PRODUCING SAME, MOISTURE-CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURED PRODUCT | KDM2B, SETDB1, ASH2L | ADRA2A 3479/4885ADRA1A 3189/4885ADRA2B 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.